Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21314738 | 0.86 | HDAC1 (0.38) | PER2HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL21314741 | 0.86 | HDAC1 (0.38) | PER2HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL30832925 | 0.86 | HDAC1 (0.38) | PER2HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL21314781 | 0.81 | RAPGEF3 (0.39) | PER2HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL30832909 | 0.81 | RAPGEF3 (0.39) | PER2HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL21314771 | 0.79 | HDAC1 (0.36) | HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL30832924 | 0.79 | HDAC1 (0.36) | HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL21314774 | 0.79 | HDAC1 (0.36) | HDAC1HDAC8HDAC6HDAC5 | |
| SCHEMBL9893128 | 0.76 | PER2 (0.48) | PER2BRD4NOTUM | |
| SCHEMBL9893095 | 0.74 | NOTUM (0.50) | PER2BRD4HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708327-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708327-B2 | Phenylpyrrolidinone formyl peptide 2 receptor agonists | FPR1, FPR2, FPR3 | PER2 1262/4885BRD4 2519/4885HDAC1 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.